References analysis of the Wikipedia article "Anticorpo de dominio simple" in the Galician version

doi.org

dx.doi.org

Harmsen MM, De Haard HJ (November 2007). "Properties, production, and applications of camelid single-domain antibody fragments". Applied Microbiology and Biotechnology 77 (1): 13–22. PMC 2039825. PMID 17704915. doi:10.1007/s00253-007-1142-2.

Möller A, Pion E, Narayan V, Ball KL (December 2010). "Intracellular activation of interferon regulatory factor-1 by nanobodies to the multifunctional (Mf1) domain". The Journal of Biological Chemistry 285 (49): 38348–61. PMC 2992268. PMID 20817723. doi:10.1074/jbc.M110.149476.

Ghannam A, Kumari S, Muyldermans S, Abbady AQ (2015). "Camelid nanobodies with high affinity for broad bean mottle virus: a possible promising tool to immunomodulate plant resistance against viruses". Plant Molecular Biology 87 (4-5): 355–69. PMID 25648551. doi:10.1007/s11103-015-0282-5.

Dolk E, van der Vaart M, Lutje Hulsik D, Vriend G, de Haard H, Spinelli S, Cambillau C, Frenken L, Verrips T (January 2005). "Isolation of llama antibody fragments for prevention of dandruff by phage display in shampoo". Applied and Environmental Microbiology 71 (1): 442–50. PMC 544197. PMID 15640220. doi:10.1128/AEM.71.1.442-450.2005.

Stanfield RL, Dooley H, Flajnik MF, Wilson IA (September 2004). "Crystal structure of a shark single-domain antibody V region in complex with lysozyme". Science 305 (5691): 1770–3. Bibcode:2004Sci...305.1770S. PMID 15319492. doi:10.1126/science.1101148.

van der Linden RH, Frenken LG, de Geus B, Harmsen MM, Ruuls RC, Stok W, de Ron L, Wilson S, Davis P, Verrips CT (April 1999). "Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies". Biochimica et Biophysica Acta 1431 (1): 37–46. PMID 10209277. doi:10.1016/S0167-4838(99)00030-8.

Harmsen MM, van Solt CB, Hoogendoorn A, van Zijderveld FG, Niewold TA, van der Meulen J (November 2005). "Escherichia coli F4 fimbriae specific llama single-domain antibody fragments effectively inhibit bacterial adhesion in vitro but poorly protect against diarrhoea". Veterinary Microbiology 111 (1–2): 89–98. PMID 16221532. doi:10.1016/j.vetmic.2005.09.005.

Harmsen MM, van Solt CB, van Zijderveld-van Bemmel AM, Niewold TA, van Zijderveld FG (September 2006). "Selection and optimization of proteolytically stable llama single-domain antibody fragments for oral immunotherapy". Applied Microbiology and Biotechnology 72 (3): 544–51. PMID 16450109. doi:10.1007/s00253-005-0300-7.

Desmyter A, Transue TR, Ghahroudi MA, Thi MH, Poortmans F, Hamers R, Muyldermans S, Wyns L (September 1996). "Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme". Nature Structural Biology 3 (9): 803–11. PMID 8784355. doi:10.1038/nsb0996-803.

Arbabi Ghahroudi M, Desmyter A, Wyns L, Hamers R, Muyldermans S (September 1997). "Selection and identification of single domain antibody fragments from camel heavy-chain antibodies". FEBS Letters 414 (3): 521–6. PMID 9323027. doi:10.1016/S0014-5793(97)01062-4.

Saerens D, Ghassabeh GH, Muyldermans S (October 2008). "Single-domain antibodies as building blocks for novel therapeutics". Current Opinion in Pharmacology 8 (5): 600–8. PMID 18691671. doi:10.1016/j.coph.2008.07.006.

Holt LJ, Herring C, Jespers LS, Woolven BP, Tomlinson IM (November 2003). "Domain antibodies: proteins for therapy". Trends in Biotechnology 21 (11): 484–90. PMID 14573361. doi:10.1016/j.tibtech.2003.08.007.

Borrebaeck CA, Ohlin M (December 2002). "Antibody evolution beyond Nature". Nature Biotechnology 20 (12): 1189–90. PMID 12454662. doi:10.1038/nbt1202-1189.

Tang Z, Feng M, Gao W, Phung Y, Chen W, Chaudhary A, St Croix B, Qian M, Dimitrov DS, Ho M (April 2013). "A human single-domain antibody elicits potent antitumor activity by targeting an epitope in mesothelin close to the cancer cell surface". Molecular Cancer Therapeutics 12 (4): 416–26. PMC 3624043. PMID 23371858. doi:10.1158/1535-7163.MCT-12-0731.

Li N, Fu H, Hewitt SM, Dimitrov DS, Ho M (August 2017). "Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma". Proceedings of the National Academy of Sciences of the United States of America 114 (32): E6623–E6631. PMC 5559039. PMID 28739923. doi:10.1073/pnas.1706055114.

Feng M, Gao W, Wang R, Chen W, Man YG, Figg WD, Wang XW, Dimitrov DS, Ho M (March 2013). "Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma". Proceedings of the National Academy of Sciences of the United States of America 110 (12): E1083–91. PMC 3607002. PMID 23471984. doi:10.1073/pnas.1217868110.

Gao W, Tang Z, Zhang YF, Feng M, Qian M, Dimitrov DS, Ho M (March 2015). "Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis". Nature Communications 6: 6536. PMC 4357278. PMID 25758784. doi:10.1038/ncomms7536.

Muyldermans S (2013). "Nanobodies: natural single-domain antibodies". Annual Review of Biochemistry 82: 775–97. PMID 23495938. doi:10.1146/annurev-biochem-063011-092449.

Rothbauer U, Zolghadr K, Tillib S, Nowak D, Schermelleh L, Gahl A, Backmann N, Conrath K, Muyldermans S, Cardoso MC, Leonhardt H (November 2006). "Targeting and tracing antigens in live cells with fluorescent nanobodies". Nature Methods 3 (11): 887–9. PMID 17060912. doi:10.1038/nmeth953.

Rothbauer U, Zolghadr K, Muyldermans S, Schepers A, Cardoso MC, Leonhardt H (February 2008). "A versatile nanotrap for biochemical and functional studies with fluorescent fusion proteins". Molecular & Cellular Proteomics 7 (2): 282–9. PMID 17951627. doi:10.1074/mcp.M700342-MCP200.

Ries J, Kaplan C, Platonova E, Eghlidi H, Ewers H (June 2012). "A simple, versatile method for GFP-based super-resolution microscopy via nanobodies". Nature Methods 9 (6): 582–4. PMID 22543348. doi:10.1038/nmeth.1991.

Koide S (August 2009). "Engineering of recombinant crystallization chaperones". Current Opinion in Structural Biology 19 (4): 449–57. PMC 2736338. PMID 19477632. doi:10.1016/j.sbi.2009.04.008.

Saerens D, Frederix F, Reekmans G, Conrath K, Jans K, Brys L, Huang L, Bosmans E, Maes G, Borghs G, Muyldermans S (December 2005). "Engineering camel single-domain antibodies and immobilization chemistry for human prostate-specific antigen sensing". Analytical Chemistry 77 (23): 7547–55. PMID 16316161. doi:10.1021/ac051092j.

Ibañez LI, De Filette M, Hultberg A, Verrips T, Temperton N, Weiss RA, Vandevelde W, Schepens B, Vanlandschoot P, Saelens X (April 2011). "Nanobodies with in vitro neutralizing activity protect mice against H5N1 influenza virus infection". The Journal of Infectious Diseases 203 (8): 1063–72. PMID 21450996. doi:10.1093/infdis/jiq168.

Hussack G, Arbabi-Ghahroudi M, van Faassen H, Songer JG, Ng KK, MacKenzie R, Tanha J (March 2011). "Neutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domain". The Journal of Biological Chemistry 286 (11): 8961–76. PMC 3058971. PMID 21216961. doi:10.1074/jbc.M110.198754.

Van de Broek B, Devoogdt N, D'Hollander A, Gijs HL, Jans K, Lagae L, Muyldermans S, Maes G, Borghs G (June 2011). "Specific cell targeting with nanobody conjugated branched gold nanoparticles for photothermal therapy". ACS Nano 5 (6): 4319–28. PMID 21609027. doi:10.1021/nn1023363.

nih.gov

ncbi.nlm.nih.gov

Borrebaeck CA, Ohlin M (December 2002). "Antibody evolution beyond Nature". Nature Biotechnology 20 (12): 1189–90. PMID 12454662. doi:10.1038/nbt1202-1189.

Muyldermans S (2013). "Nanobodies: natural single-domain antibodies". Annual Review of Biochemistry 82: 775–97. PMID 23495938. doi:10.1146/annurev-biochem-063011-092449.

Koide S (August 2009). "Engineering of recombinant crystallization chaperones". Current Opinion in Structural Biology 19 (4): 449–57. PMC 2736338. PMID 19477632. doi:10.1016/j.sbi.2009.04.008.

web.archive.org

Gibbs, W. Wayt (August 2005). "Nanobodies". Scientific American. Arquivado dende o orixinal o 10 de outubro de 2007. Consultado o 04 de abril de 2018.

"Pipeline". Ablynx. Arquivado dende o orixinal o 04 de xaneiro de 2010. Consultado o 20 January 2010.

"Ablynx Announces Interim Results of First Nanobody Phase I Study of,ALX-0081 (ANTI-VWF)". Bio-Medicine.org. 2 July 2007. Arquivado dende o orixinal o 16 de febreiro de 2021. Consultado o 04 de abril de 2018.

Anticorpo de dominio simple (Galician Wikipedia)

ablynx.com

archive.org

bio-medicine.org

clinicaltrials.gov

doi.org

dx.doi.org

harvard.edu

adsabs.harvard.edu

nanobody.org

news-medical.net

nih.gov

ncbi.nlm.nih.gov

sciam.com

web.archive.org